Lilly Q3 Revenue Jumps 39% to $24.4B; IPR&D Charges Surge to $4.2B
LLY sits 68% above its 52-week low of $809.63.
Summary
Lilly posted Q3 revenue of $24.4B (+39%) and diluted EPS of $7.22, but $4.2B of acquired IPR&D charges from the AtaiBeckley and Curevo deals capped net income growth at 16%.
Key Events · Earnings and Guidance · LLY
-
Q3 Revenue Up 39% to $24.4B
Revenue rose to $24,397M from $17,601M, with Mounjaro at $10,723M and Zepbound at $5,352M for the quarter; nine-month revenue reached $67,170M, up 46%.
-
IPR&D Charges Cap Earnings Growth
Acquired IPR&D charges were $4,181M in Q3 versus $656M a year ago, driven by AtaiBeckley ($2,610M) and Curevo ($954M); net income rose only 16% to $6,451M and diluted EPS to $7.22.
-
Cash Down, Debt Up on Deal Spree
Cash and equivalents fell to $4,885M from $7,268M at December 31, 2025, while total debt rose to $49.5B from $42.5B after a $9.0B May 2026 bond issuance.
-
Merida Acquisition Follows Quarter-End
In October 2026 Lilly acquired Merida Biosciences for up to $2.9B in aggregate, inclusive of upfront and milestone payments; fair-value accounting is still being determined.
Analysis · LLY · Life Sciences
Top-line momentum remains intact: Q3 revenue of $24.4B is up 39%, and nine-month revenue of $67.2B is up 46%, with Mounjaro at $10.7B and Zepbound at $5.4B for the quarter. The offset sits below the gross-margin line. Acquired IPR&D charges ballooned to $4.2B in Q3 (versus $656M a year ago) on the AtaiBeckley and Curevo deals, and $7.5B for nine months, which is why net income grew only 16% to $6.5B despite the revenue surge. Cash fell to $4.9B from $7.3B at year-end while total debt rose to $49.5B from $42.5B, funding an acquisition spree that continued into October with Merida Biosciences for up to $2.9B. The pipeline is paying off — orforglipron (Foundayo) is now FDA-approved for obesity and tirzepatide won a cardiovascular-risk label — but the earnings quality depends on how much more cash management pours into bolt-on deals.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LLY was trading at $1,363.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $809.63 to $1,408.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.